18F-FDOPA PET/CT for detection of recurrence in patients with glioma: Prospective comparison with 18F-FDG PET/CT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 7, 2013, Pages 1025-1035

  Karunanithi, Sellam ^a   Sharma, Punit ^a   Kumar, Abhishek ^a   Khangembam, Bangkim Chandra ^a   Bandopadhyaya, Guru Pada ^a   Kumar, Rakesh ^a   Gupta, Deepak Kumar ^a   Malhotra, Arun ^a   Bal, Chandrasekhar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

18F FDG; 18F FDOPA; Glioma; PET CT; Recurrence

Indexed keywords

3,4 DIHYDROXY 6 FLUORO PHENYLALANINE F 18; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; 6 FLUORODOPA F 18; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GLIOMA; HISTOPATHOLOGY; HUMAN; MALE; PET SCANNER; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; REOPERATION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR DIAGNOSIS; TUMOR RECURRENCE; BRAIN TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; STANDARD; YOUNG ADULT; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE; PROCEDURES; STANDARDS;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; DIHYDROXYPHENYLALANINE; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RECURRENCE; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84879505266     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2384-0     Document Type: Article

References (28)

1. Levin VA, Prados MD. Treatment of recurrent gliomas and, metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol. 1992;10:766-71.
2. Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol. 1994;19:69-74.
3. Patronas NJ, Di Chiro G, Brooks RA, DeLaPaz RL, Kornblith PL, Smith BH, et al. Work in progress: [18F]fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology. 1982;144:885-9.
4. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy and survival in malignant glioma, a retrospective study of clinical parameters, therapy and outcomes. J Neurosurg. 1993;78:767-75.
5. Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, et al. Optimum cut off levels of FDG uptake in differentiation of low grade from high grade brain tumors with PET. Radiology. 1995;195:47-52.
6. Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, et al. PET in patients of glioma, a predictor of prognosis. Cancer. 1988;62:1074-8.
7. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-45.
8. Herholz K, Holzer T, Bauer B, Schröder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-22.
9. Coope DJ, Cizek J, Eggers C, Vollmar S, Heiss WD, Herholz K. Evaluation of primary brain tumors using 11Cmethionine PET with reference to a normal methionine uptake map. J Nucl Med. 2007;48:1971-80.
10. Laverman P, Boerman OC, Corstens FH, Oyen WJ. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging. 2002;29:681-90.
11. Bethien-Baumann B, Bredow J, Burchert W, Füchtner F, Bergmann R, Alheit HD, et al. 3-O-Methyl-6-[18F]fluoro-LDOPA and its evaluation in brain tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:1004-8.
12. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904-11.
13. Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561-7.
14. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, et al. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009;71:242-8.
15. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010;51:1532-8.
16. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. 18F-FDOPA kinetics in brain tumors. J Nucl Med. 2007;48:1651-61.
17. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol. 1988;150:189-97.
18. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001;96:191-7.
19. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol. 1998;19:407-13.
20. Asensio C, Pérez-Castejón MJ, Maldonado A, Montz R, Ruiz JA, Santos M, et al. The role of PET-FDG in questionable diagnosis of relapse in the presence of radionecrosis of brain tumors. Rev Neurol. 1998;27:447-52.
21. Belohlávek O, Klener J, Vymazal J, Dbalý V, Tovarys F. The diagnostics of recurrent gliomas using FDG-PET: still questionable? Nucl Med Rev Cent East Eur. 2002;5:127-30.
22. Doyle WK, Budinger TF, Valk PE, Levin VA, Gutin PH. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr. 1987;11:563-70.
23. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778-85.
24. Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176-82.
25. Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45:1293-8.
26. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39-51.
27. Henze M, Mohammed A, Schlemmer HP, Herfarth KK, Hoffner S, Haufe S, et al. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis. J Nucl Med. 2004;45:579-86.
28. Tripathi M, Sharma R, D'Souza M, Jaimini A, Panwar P, Varshney R, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2009;34:878-83.